GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus.
de Sá. Larissa Bianca Paiva Cunha LB; Nascif. Sergio Oliva SO; Correa-Silva. Silvia Regina SR; Molica. Patricia P; Vieira. José Gilberto Henriques JG; Dib. Sergio Atala SA; Lengyel. Ana-Maria Judith AM
Key Findings
- Fasting growth hormone levels are higher in type‑1 diabetics than in controls.
- GHRP‑6 and ghrelin both raise growth hormone, but ghrelin produces a larger spike than GHRP‑6 in both groups.
- ACTH and cortisol responses to GHRP‑6 and ghrelin are comparable between diabetics and healthy subjects.
Practical Outcomes
- For biohackers, this study mainly confirms that GHRP‑6 works as a growth‑hormone secretagogue regardless of type‑1 diabetes status. It doesn’t suggest new dosing strategies or unique benefits, but it provides modest safety reassurance that the peptide’s hormonal effects aren’t impaired in diabetic individuals.
Summary
The study looked at how the hormone‑releasing peptide GHRP‑6 (and ghrelin) affect growth hormone, ACTH, and cortisol in people with type‑1 diabetes compared to healthy folks. It found that both groups respond similarly – the peptides still boost growth hormone, and they don’t change ACTH or cortisol differently. In short, having type‑1 diabetes doesn’t seem to blunt the hormone‑releasing effects of GHRP‑6.
Abstract
In type 1 diabetes mellitus (T1DM), growth hormone (GH) responses to provocative stimuli are normal or exaggerated, whereas the hypothalamic-pituitary-adrenal axis has been less studied. Ghrelin is a GH secretagogue that also increases adrenocorticotropic hormone (ACTH) and cortisol levels, similarly to GH-releasing peptide-6 (GHRP-6). Ghrelin's effects in patients with T1DM have not been evaluated. We therefore studied GH, ACTH, and cortisol responses to ghrelin and GHRP-6 in 9 patients with T1DM and 9 control subjects. The GH-releasing hormone (GHRH)-induced GH release was also evaluated. Mean fasting GH levels (micrograms per liter) were higher in T1DM (3.5 ± 1.2) than in controls (0.6 ± 0.3). In both groups, ghrelin-induced GH release was higher than that after GHRP-6 and GHRH. When analyzing Δ area under the curve (ΔAUC) GH values after ghrelin, GHRP-6, and GHRH, no significant differences were observed in T1DM compared with controls. There was a trend (P = .055) to higher mean basal cortisol values (micrograms per deciliter) in T1DM (11.7 ± 1.5) compared with controls (8.2 ± 0.8). No significant differences were seen in ΔAUC cortisol values in both groups after ghrelin and GHRP-6. Mean fasting ACTH values were similar in T1DM and controls. No differences were seen in ΔAUC ACTH levels in both groups after ghrelin and GHRP-6. In summary, patients with T1DM have normal GH responsiveness to ghrelin, GHRP-6, and GHRH. The ACTH and cortisol release after ghrelin and GHRP-6 is also similar to controls. Our results suggest that chronic hyperglycemia of T1DM does not interfere with GH-, ACTH-, and cortisol-releasing mechanisms stimulated by these peptides.
Study Information
pubmed
2010
2010-03-01T00:00:00.000Z
10.1016/j.metabol.2010.01.021
7
51